Oxymetazoline

Revision as of 19:33, 27 September 2011 by WikiBot (talk | contribs) (Protected "Oxymetazoline": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
Jump to navigation Jump to search
Oxymetazoline
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC16H24N2O
Molar mass260.375 g·mol−1
Melting point301.5 °C (574.7 °F)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

WikiDoc Resources for Oxymetazoline

Articles

Most recent articles on Oxymetazoline

Most cited articles on Oxymetazoline

Review articles on Oxymetazoline

Articles on Oxymetazoline in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Oxymetazoline

Images of Oxymetazoline

Photos of Oxymetazoline

Podcasts & MP3s on Oxymetazoline

Videos on Oxymetazoline

Evidence Based Medicine

Cochrane Collaboration on Oxymetazoline

Bandolier on Oxymetazoline

TRIP on Oxymetazoline

Clinical Trials

Ongoing Trials on Oxymetazoline at Clinical Trials.gov

Trial results on Oxymetazoline

Clinical Trials on Oxymetazoline at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Oxymetazoline

NICE Guidance on Oxymetazoline

NHS PRODIGY Guidance

FDA on Oxymetazoline

CDC on Oxymetazoline

Books

Books on Oxymetazoline

News

Oxymetazoline in the news

Be alerted to news on Oxymetazoline

News trends on Oxymetazoline

Commentary

Blogs on Oxymetazoline

Definitions

Definitions of Oxymetazoline

Patient Resources / Community

Patient resources on Oxymetazoline

Discussion groups on Oxymetazoline

Patient Handouts on Oxymetazoline

Directions to Hospitals Treating Oxymetazoline

Risk calculators and risk factors for Oxymetazoline

Healthcare Provider Resources

Symptoms of Oxymetazoline

Causes & Risk Factors for Oxymetazoline

Diagnostic studies for Oxymetazoline

Treatment of Oxymetazoline

Continuing Medical Education (CME)

CME Programs on Oxymetazoline

International

Oxymetazoline en Espanol

Oxymetazoline en Francais

Business

Oxymetazoline in the Marketplace

Patents on Oxymetazoline

Experimental / Informatics

List of terms related to Oxymetazoline

Overview

Oxymetazoline is a topical decongestant used, in the form of Oxymetazoline hydrochloride, in products such as Nasivion, Vicks Sinex and Afrin. Oxymetazoline is generally available as a nasal spray. If overused it can cause a "rebound congestion" (rhinitis medicamentosa) where the tissues of the sinuses are damaged, become swollen, and therefore become congested after the drug wears off. As a result, a user can develop physiological tolerance to the drug, manifested by prolonged nasal congestion without continued use of the medication. (See the discussion of the effect of benzalkonium chloride, a common additive to oxymetazoline nasal sprays, in the article Rhinitis medicamentosa.)

The medication has sympathomimetic properties, and thus constricts the blood vessels of the nose and sinuses via activation of alpha1 adrenergic receptors, in turn causing less production of mucous. It is frequently used by anaesthesiologists to reduce nasal bleeding during nasal endotracheal intubations. This drug, not unlike most sympathomimetic amines, has adrenaline-releasing properties due to its mode of action. However, since the application is topical, it has practically no CNS stimulation as of the systemic application of decongestants such as pseudoephedrine.

Since no clinical data on exposed pregnancies are available with oxymetazoline, the safe use of oxymetazoline during pregnancy has not been established.

If accidentally ingested, standard methods to remove unabsorbed drugs should be considered. There is no specific antidote for oxymetazoline. In children, oxymetazoline may produce profound central nervous system depression.

Oxymetazoline HCl 0.025% is also the active ingredient in Visine L.R. Long-Lasting Redness Relief eye drops.

Template:SIB
he:אוקסימטזולין hu:Oxymetazolin nl:Oxymetazoline Template:WH Template:WikiDoc Sources